Introduction
============

Breast cancer (BC) is recognized as the most common malignant tumor and the leading cause of cancer-related death among females all over the world [@B1]. In China, breast cancer was responsible for around 268,600 new cases and 69,500 deaths in 2015 [@B2]. Studies have identified environmental factors as the risk for breast cancer, involving reproductive and hormonal factors including a long menstrual history, oral contraceptives use and never having children [@B1]. Also, genetic backgrounds play a vital role in the etiology of breast cancer. Previous researches have reported that a number of genetic variants were associated with the risk of BC [@B3]-[@B5]. However, the occurrence of BC is a complex multifactorial process and the molecular mechanism remains largely unclear.

Long non-coding RNAs (LncRNAs) are a new class of regulatory non-coding RNAs with length longer than 200 nucleotides, lacking open reading frame and having no potential protein translation capacity [@B6]. Recently, many studies have revealed that aberrant expression of lncRNAs was significantly associated with tumorigenesis and tumor progression in different cancer types, indicating the lncRNAs act as proto-oncogene [@B7] or anti-oncogene [@B8]. In addition, lncRNAs are considered to be involved in complex pathogenesis of cancers, referring to the levels of epigenome, transcription and post-transcription [@B9]. LncRNAs have essential roles in multiple biological processes including chromatin remodeling, cell differentiation, cell cycle control, genome rearrangement, dosage compensation, gene imprinting and regulation of gene expression [@B10]. Study demonstrated that the lncRNA *HOTAIR* was overexpressed in BC tissues and participated in BC progression [@B9]. Also, up-regulated lncRNA *MALAT1* was detected in lung adenocarcinoma, which predicted metastasis and poor prognosis in early-stage non-small cell lung cancer [@B11]. Additionally, research has shown that lncRNA *MEG3* expression was down-regulated in gastric cancer tissues and cell lines, and was associated with metastasis of gastric cancer by its function as a competing endogenous RNA (ceRNA) of miR-181s to regulate gastric cancer progression [@B12].

SNPs in lncRNAs may affect the function of target genes through altering the process of splicing and stability of mRNA conformation, leading to the modification of their interacting partners [@B13]. To date, the susceptibility of lncRNA SNPs to cancer risk have been investigated by numerous researches, such as lncRNA *HOTAIR* rs920778 polymorphism cause *HOTAIR* up-regulated among T allele carriers, which enhancing esophageal squamous cell carcinoma (ESCC)[@B14] and cervical cancer [@B15] risk in a Chinese population. However, Bayram *et al.* [@B16] reported that *HOTAIR* rs920778 CC genotype significantly increased the BC risk in a Turkish population. In addition, it was identified that lncRNA *HULC* rs7763881 may decrease the risk of HBV-related hepatocellular carcinoma in a Chinese population [@B17]. Subsequently, genome-wide association studies (GWAS) have identified that the C allele carriers of rs12325489 in the lincRNA-ENST00000515084 are associated with increased BC risk [@B18].

Based on the above backgrounds, the SNPs in the lncRNAs were the susceptibility of BC, and could be invested as biomarkers for the risk of BC. To date, there is no research to evaluate the susceptibility of lncRNA *PTCSC3* rs944289, lncRNA *POLR2E* rs3787016, lncRNA *PRNCR1* rs1456315 and lncRNA *PRNCR1*rs7463708 to BC risk. Therefore, in the current study, we selected these four tagSNPs in the lncRNAs and evaluated the relationships between the four SNPs and the risk of BC in a Chinese female population.

Materials and Methods
=====================

Study subjects
--------------

A total of 878 age-matched female subjects divided into case cohort with 439 BC patients and health cohort with 439 cancer-free individuals were enrolled in this population-based case-control study. All the patients were genetically unrelated and consecutively recruited starting from January 2008 to January 2016 in Nanjing First Hospital, Nanjing Medical University, China. Meanwhile, the health controls were randomly collected in the same hospital for their routine physical checkup at the same time period. For the cases and controls, a pretested questionnaire was used to record clinical information of each individual, such as tobacco smoking, alcohol consumption and other cancer history. Owing to less than ten individuals have the history of smoking and drinking, which may be attributed to the life style of Chinese female, and considering the very small size of participants has these two environmental factors, finally we adjusted inclusion criteria of cases as follows: (1) subjects were histologically diagnosed with primary BC; (2) with no history of smoking and drinking; (3) with no evidence of personal or family history of cancer. Selection criteria for controls included no prior history of cancer or other malignant conditions and without history of smoking and drinking. All participants have given written informed consents, and this study was approved by the Institutional Review Board of the Nanjing First Hospital.

SNPs genotyping
---------------

We collected these blood samples from each individual after their admission to the hospital. The whole blood samples of all participants collected in a test tube containing EDTA were used for genotyping assay. Genomic DNA was isolated from peripheral white blood and concentrated by using GoldMag-Mini Whole Blood Genomic DNA Purification Kit according to the manufacturer\'s directions (GoldMag Co. Ltd. Xian, China). The extracted DNA was stored at -80℃ until use. We adopted the spectrometry (DU530 UV/vis spectrophotometer, Beckman Instruments, Fullerton, CA, USA) to detect DNA purity. Sequenom MassARRAY Assay Design 3.0 Software was used to design Multiplexed SNP MassEXTEND assay [@B19]. PCR and extension primers were designed by Sequenom, Inc. Assay Design. EXO-SAP was used to digest PCR-amplified DNA, and then mixed the primer extended by IPLEX chemistry, desalted using Clean Resin (Sequenom) and spotted onto Spectrochip matrix chips. Finally, results were detected by Mass Spectrometer. All samples were genotyped by Sequenom MassARRAY RS1000 according to the manufacturer\'s protocol. The final data was managed and analysed by Sequenom Typer 4.0 Software [@B19], [@B20].

Immunohistochemistry (IHC) assay
--------------------------------

The immunohistochemistry (IHC) assay was applied to evaluate the expression of estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER-2) in paraffin-embedded tumor tissue[@B21]. The immunohistochemical analysis was conducted following the instructions inside the kit. The monoclonal rabbit ER, PR and HER-2 antibody used in this study were purchased from Spring Bioscience (Pleasanton, CA, USA).

Statistical analysis
--------------------

Hardy-Weinberg equilibrium (HWE) was assessed by a goodness of fit chi-square test among the healthy controls to compare the observed genotype frequencies with the expected ones. The two-sided χ^2^ test and independent t test were used to compare the selected variables between BC patients and healthy controls. Associations of the four SNPs with BC risks were estimated by a logistic regression model with odds ratios (ORs) and 95% confidence intervals (CIs), corresponding *p* values after adjustment for age and menopausal status. All statistical analysis was performed by using SPSS 23.0 for Windows (SPSS, Chicago, IL) and the *P* value \< 0.05 was considered to be statistically significant.

Results
=======

A total of 878 age-matched Chinese women subjects (439 BC patients and 439 healthy controls) were enrolled in this population-based case-control study to investigate the potential association between the four tagSNPs (rs944289, rs3787016, rs1456315, rs7463708) in the lncRNAs and BC risk. Clinicopathological features of patients with BC and healthy controls were summarized in Table [1](#T1){ref-type="table"}, there were no statistically significant differences in age and menopausal status (mean age of patients *vs.*controls: 52.89±10.78 years *vs.* 52.95±10.89 years, *P*= 0.933; number of postmenopausal cases *vs.* controls: 241 *vs.*229, *P*= 0.417). The observed genotype frequencies of the four SNPs in healthy controls were no significant deviations from the Hardy-Weinberg equilibrium (HWE) (*P*= 0.078 for rs944289, *P*= 0.144 for rs3787016, *P*= 0.167 for rs1456315 and*P*= 0.142 for rs7463708, respectively).

The genotypes and alleles distribution of the four tagSNPs in BC patients and healthy controls are presented in Table [2](#T2){ref-type="table"}. Logistic regression analysis revealed that the rs3787016 TT homozygote (adjusted OR = 1.62, 95% CI: 1.09-2.41, *P*= 0.018) was associated with increased risk of BC when compared with the wild-type CC homozygote. Also, a borderline significantly increased risk was observed in the T allele of rs3787016 (adjusted OR = 1.21, 95% CI: 1.00-1.46, *P*= 0.052) for BC when compared with the C allele. However, no statistically significant association between rs944289, rs1456315 and rs7463708 and the risk of BC was observed among all participants, as shown in Table [2](#T2){ref-type="table"}.

To identify the stratified effects of SNPs in lncRNAs on BC risk, subgroup analysis based on the menopausal status was performed and logistic regression analysis revealed that rs3787016 TT genotype carriers (adjusted OR = 2.55, 95% CI: 1.30-4.97, *P*= 0.006) have higher BC risk than those with wild-type CC in the premenopausal sub-cohort; in contrast, in the subgroup of postmenopausal women, rs7463708 GT genotype (adjusted OR = 0.67, 95% CI: 0.46-0.99, *P*= 0.043) or rs7463708 GT/GG genotype (adjusted OR = 0.68, 95% CI: 0.47-0.98, *P*= 0.041) was associated with decreased risk of BC when compared with the wild-type TT, as summarized in Table [3](#T3){ref-type="table"}.

Moreover, we demonstrated the association of the four SNPs with the pathological characteristics (tumor stage, tumor grade and lymph node involvement) and patient\'s tumor tissue characteristics (expression of ER, PR and HER-2). As shown in Table [4](#T4){ref-type="table"}, we found that rs3787016 TT genotype was associated with advanced TNM (Ⅲ and Ⅳ) classification (adjusted OR = 2.57, 95% CI: 1.45-4.56, *P*= 0.001), poor histological grade (G3-G4) (adjusted OR = 1.92, 95% CI: 1.07-3.46, *P*= 0.029) and positive lymph node involvement (adjusted OR = 1.79, 95% CI: 1.11-2.89, *P*= 0.016). In addition, a marginal significance of increased risk for BC with early differentiation (G1-G2) (adjusted OR = 1.53, 95% CI: 1.00-2.36, *P*= 0.053) was noticed. Also, we determined a statistically significant inverse relationship between the GT genotype (adjusted OR = 0.65, 95% CI: 0.43-0.97, *P*= 0.037) or GT/GG genotype (adjusted OR = 0.65, 95% CI: 0.44-0.96, *P*= 0.029) of rs7463708 polymorphism and tumor late-stage (Ⅲ and Ⅳ). Furthermore, subgroup analysis based on expression of ER, PR and HER-2 was presented in the Table [5](#T5){ref-type="table"}. Similarly, we observed that rs3787016 TT genotype was associated with increased BC risk of positive expression of ER (adjusted OR = 1.69, 95% CI: 1.08-2.64, *P*= 0.021) and PR (adjusted OR = 1.75, 95% CI: 1.10-2.79, *P*= 0.019) and negative expression of HER-2 (adjusted OR = 2.10, 95% CI: 1.14-3.88, *P*= 0.017), respectively. However, there was no significant association for the three SNPs (rs944289, rs1456315, rs7463708) in all subgroups, as shown in Table [5](#T5){ref-type="table"}.

Discussion
==========

In this population-based case-control study, we investigated the association between the four selected SNPs in the lncRNAs and the risk of female BC in a Chinese population. We observed that rs3787016 TT genotype was associated with an increased risk of female BC and clinicopathologic features of the tumor, especially among premenopausal women.

The SNP rs3787016 is in a lncRNA which located in an intron region of RNA polymerase Ⅱ subunit E (*POLR2E*) gene, which encodes the fifth largest subunit of RNA polymerase II and is responsible for synthesizing messenger RNA (mRNA) in eukaryotes. Previous study suggested the functional genetic variants in lncRNA regions may contribute to carcinogenesis [@B22]. Moreover, the rs3787016 TT genotype was investigated to be associated with increased risk of prostate cancer in an eastern Chinese population [@B23], which was consistent with the result of the study containing a meta-analysis of two GWAS and a case-control study [@B22]; however, such a significant association could not be duplicated in a Serbian population [@B24]. This study indicated that the rs3787016 TT genotype was a risk factor for female BC in a Chinese population. In contrast, a case-control study of ESCC demonstrated that *POLR2E* rs3787016 CT or CT/TT genotype had a decreased risk of ESCC [@B25]. The different findings in the above studies might be explained as follow. Firstly, the results of association studies may vary among different cancer types. Secondly, owing to ancestral backgrounds, inter-population genetic differences including differences in allele frequencies could lead to inconsistent results. Finally, ESCC is considered to be affected by multiple environmental factors exposures and the interaction of the genetic backgrounds and environmental factors contributes to the risk of cancer, so the association of genetic variants and ESCC risk should be validated by more researches. Subsequently, subgroup analysis of this study revealed that the carriers of rs3787016 TT genotype had more evident risk effect on patients with positive expression of ER and PR. As we known, the expression of these two receptors is closely related to the menopausal status of females, and women in the premenopausal status have more estrogen and progesterone, which may be attributed to the result concluded by this study that patients with rs3787016 TT genotype have higher BC risk in the premenopausal sub-cohort.

The SNP rs1456315 is located in the prostate cancer associated noncoding RNA 1 (*PRNCR1*), which is a \~13kb lncRNA transcribed from the "gene desert" region of chromosome 8q24 (128.14-128.28Mb). SNPs in the lncRNA *PRNCR1* have been reported to influence the secondary structure of *PRNCR1* mRNA and the stability of the mRNA conformation, resulting in the occurrence and development of human diseases [@B26]; in addition, rs1456315 positioned in the region 2 of 8q24 was significantly associated with prostate cancer susceptibility [@B26]. Subsequently, study reported that rs1456315 AG genotype may contribute to a decreased risk of colorectal cancer [@B27]. However, in the present study, no statistically significant association was observed between the rs1456315 and the risk of BC. The inconsistent conclusions may be attributed to the different kinds of cancer. Also, this is the first study investigated the relationship between the rs1456315 and BC risk, so further large-scale studies in different populations still need to be done.

Rs7463708 overlaps with the lncRNA *PRNCR1*and is located in an enhancer of prostate cancer associated transcript 1 (*PCAT1*) 78 kb away, which is a lncRNA positioned in the 8q24 "gene desert" region and overexpressed in prostate cancer. It was reported that the *PCAT1*promoter strongly interacted with the T allele of rs7463708, suggesting that rs7463708 regulated the activation of *PCAT1*enhancer and resulted in increased *PCAT1*expression [@B28], [@B29]. In addition, *PCAT1* plays an important role in the carcinogenesis through interacting with the *GNMT* gene involving in prostate cancer [@B29] and modulating mTOR signaling pathway in hepatocellular carcinoma [@B30], which also participating in the development of BC [@B31]. Thus, it is possible that the rs7463708 have potential association with BC risk. Also, our study drew a conclusion that in the sub-cohort analysis, rs7463708 GT and GT/GG genotypes were protective factors for female BC among postmenopausal status and tumor late-stage. To date, there was no study investigated the association between the rs7463708 and cancer risk except for prostate cancer risk. This is the first time investigating the association of rs7463708 and BC risk; therefore, more researches should be conducted for further study.

The SNP rs944289 at 14q13.3 is located 3.2 kb upstream of a long intergenic noncoding RNA (lincRNA) named Papillary Thyroid Carcinoma Susceptibility Candidate 3 (*PTCSC3*) and positioned in the binding site of the CCAAT/enhancer binding proteins (C/EBP) α and β [@B32]. The rs944289 T allele can affect binding sequence and results in missense variant and amino acid substitution (valine instead of alanine at codon 339), which may be induce multinodular goiter and papillary thyroid cancer (PTC)[@B33]. Up to now, all published researches were assessed the relationships between the rs944289 and differentiated thyroid carcinoma (DTC) [@B34]-[@B37]; however, to date, no association of other cancer types was discussed with the SNP, which may be due to the specific susceptibility of the SNP to the risk of DTC, and in this study, we also observed no significant relationships between the rs944289 and BC risk.

To our knowledge, in the present study, we investigated the association between the four selected SNPs and BC risk for the first time. Although there were some important discoveries revealed in the study, several limitations also need to be addressed. Firstly, the four selected SNPs of lncRNAs in our study may not be comprehensive because we were limited by those have been identified to have risk effect on other cancers. Also, the biological function of these lncRNAs remains largely unknown and has not been validated in experimental models, so it is difficult to explain our results. Secondly, the number of subjects in our study is not enough large and the small size in subgroup analysis may not provide statistical power to show significant results. Moreover, the clinical information of each individual is not fully reliable and detailed, which might influence the accuracy of the results. Thirdly, BC is a complex and multifactorial disease, this is not a large size population based case-control study, and the samples was not enough for the sub-group analysis, therefore, to confirm our findings, studies with more large-scale samples including different ethnic populations and detailed clinical information should be conducted. In addition, properly functional assessments also should be performed to illuminate the etiology of the BC.

In summary, this study demonstrated that rs3787016 TT genotype was associated with BC risk and clinicopathologic features of the tumor, especially among premenopausal women. Nevertheless, the results of this preliminary study need to be validated by further larger and well-designed researches.
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###### 

Clinicopathological features of patients with breast cancer and healthy controls

  Variables                    Cases, n (%)   Controls, n (%)   *P* value^a^
  ---------------------------- -------------- ----------------- --------------
  **Total participants**       439            439               
  **Age(Mean±SD, years)**      52.89±10.78    52.95±10.89       0.933
  **Menopausal status**                                         0.417
  Premenopausal                198(45.10%)    210(47.84%)       
  Postmenopausal               241(54.90%)    229(52.16%)       
  **Tumor stage**                                               
  0-Ⅱ                          306(69.70%)                      
  Ⅲ-Ⅳ                          133(30.30%)                      
  **Tumor grade**                                               
  G1-G2                        317(72.21%)                      
  G3-G4                        122(27.79%)                      
  **Lymph node involvement**                                    
  Negative                     211(48.06%)                      
  Positive                     228(51.94%)                      
  **ER**                                                        
  Negative                     166(37.81%)                      
  Positive                     273(62.19%)                      
  **PR**                                                        
  Negative                     205(46.70%)                      
  Positive                     234(53.30%)                      
  **HER-2**                                                     
  Negative                     92(20.96%)                       
  Positive                     347(79.04%)                      

^a^Two-sided χ^2^ test and independent t test for the selected variables between cases and controls.

ER, estrogen receptor; PR, progesterone receptor; HER-2, human epidermal growth factor receptor-2

###### 

Genotypes and allele frequencies of the four SNPs between patients with breast cancer and healthy controls

  Genotype    Cases, n(%)   Controls, n(%)   Crude OR(95%CI)       *P* value   Adjusted OR(95%CI)^a^   *P* value^a^
  ----------- ------------- ---------------- --------------------- ----------- ----------------------- --------------
  rs944289                                                                                             
  CC          127(28.93)    115(26.20)       Reference                         Reference               
  CT          229(52.16)    237(53.99)       0.88(0.64,1.19)       0.400       0.88(0.64,1.20)         0.402
  TT          83(18.91)     87(19.82)        0.86(0.58,1.28)       0.465       0.86(0.58,1.28)         0.453
  CT/TT       312(71.07)    324(73.80)       0.87(0.65,1.17)       0.365       0.87(0.65,1.17)         0.368
  Allele                                                                                               
  C           483(55.01)    467(53.19)       Reference                         Reference               
  T           395(44.99)    411(46.81)       0.93(0.77,1.12)       0.444       0.93(0.77,1.12)         0.442
  rs3787016                                                                                            
  CC          137(31.21)    149(33.94)       Reference                         Reference               
  TC          209(47.61)    226(51.48)       1.01(0.75,1.36)       0.970       1.02(0.76,1.38)         0.894
  TT          93(21.18)     64(14.58)        **1.58(1.07,2.34)**   **0.023**   **1.62(1.09,2.41)**     **0.018**
  TC/TT       302(68.79)    290(66.06)       1.13(0.85,1.50)       0.388       1.13(0.85,1.51)         0.384
  Allele                                                                                               
  C           483(55.01)    524(59.68)       Reference                         Reference               
  T           395(44.99)    354(40.32)       **1.21(1.01,1.46)**   **0.048**   1.21(1.00,1.46)         0.052
  rs1456315                                                                                            
  AA          234(53.30)    244(55.58)       Reference                         Reference               
  GA          165(37.59)    159(36.22)       1.08(0.82,1.44)       0.584       1.08(0.81,1.43)         0.607
  GG          40(9.11)      36(8.20)         1.16(0.71,1.88)       0.552       1.16(0.71,1.88)         0.555
  GA/GG       205(46.70)    195(44.42)       1.10(0.84,1.43)       0.498       1.09(0.84,1.43)         0.511
  Allele                                                                                               
  A           633(72.10)    647(73.69)       Reference                         Reference               
  G           245(27.90)    231(26.31)       1.08(0.88,1.34)       0.452       1.08(0.88,1.34)         0.460
  rs7463708                                                                                            
  TT          209(47.61)    184(41.91)       Reference                         Reference               
  GT          190(43.28)    211(48.06)       0.79(0.60,1.05)       0.103       0.79(0.60,1.05)         0.102
  GG          40(9.11)      44(10.02)        0.80(0.50,1.28)       0.355       0.81(0.50,1.30)         0.380
  GT/GG       230(52.39)    255(58.09)       0.79(0.61,1.04)       0.090       0.79(0.61,1.04)         0.090
  Allele                                                                                               
  T           608(69.25)    579(65.95)       Reference                         Reference               
  G           270(30.75)    299(34.05)       0.86(0.70,1.05)       0.139       0.86(0.70,1.05)         0.139

^a^Adjusted by age and menopausal status in logistic regression analysis.

The bold values indicate statistically significant data

###### 

Stratified effects of polymorphisms in lncRNAs on breast cancer risk by menopausal status

  Genotype    Premenopausal                         *P* value^a^   Postmenopausal                         *P* value^a^
  ----------- --------------- --------------------- -------------- ---------------- --------------------- --------------
  rs944289                                                                                                
  CC          55/54           Reference                            72/61            Reference             
  CT          110/112         0.97(0.61,1.53)       0.879          119/125          0.81(0.53,1.23)       0.319
  TT          33/44           0.74(0.41,1.33)       0.312          50/43            0.97(0.56,1.66)       0.903
  CT/TT       143/156         0.90(0.58,1.40)       0.638          169/168          0.85(0.57,1.27)       0.428
  rs3787016                                                                                               
  CC          61/65           Reference                            76/84            Reference             
  TC          97/128          0.79(0.51,1.23)       0.304          112/98           1.23(0.81,1.87)       0.324
  TT          40/17           **2.55(1.30,4.97)**   **0.006**      53/47            1.25(0.75,2.08)       0.387
  TC/TT       137/145         1.01(0.66,1.54)       0.970          165/145          1.24(0.85,1.82)       0.272
  rs1456315                                                                                               
  AA          99/113          Reference                            135/131          Reference             
  GA          81/78           1.18(0.78,1.78)       0.431          84/81            0.99(0.67,1.47)       0.971
  GG          18/19           1.08(0.54,2.17)       0.832          22/17            1.24(0.63,2.44)       0.540
  GA/GG       99/97           1.16(0.79,1.72)       0.444          106/98           1.04(0.72,1.49)       0.855
  rs7463708                                                                                               
  TT          85/87           Reference                            124/97           Reference             
  GT          93/100          0.96(0.63,1.44)       0.826          97/111           **0.67(0.46,0.99)**   **0.043**
  GG          20/23           0.89(0.46,1.74)       0.733          20/21            0.74(0.38,1.43)       0.366
  GT/GG       113/123         0.94(0.64,1.39)       0.760          117/132          **0.68(0.47,0.98)**   **0.041**

^a^Adjusted by age

The results with significant difference are in bold

###### 

Stratified effects of SNPs in lncRNAs on breast cancer risk by the pathological characteristics of patients

  Genotype    Co    Stage(0-Ⅱ)   *P* value^a^      Stage(Ⅲ-Ⅳ)   *P* value^a^   Grade(G1-G2)          *P* value^a^   Grade(G3-G4)   *P* value^a^      Lymph node involvement(-)   *P* value^a^   Lymph node involvement(+)   *P* value^a^                                                               
  ----------- ----- ------------ ----------------- ------------ -------------- --------------------- -------------- -------------- ----------------- --------------------------- -------------- --------------------------- -------------- ----- ----------------- ------- ----- --------------------- -----------
  rs944289                                                                                                                                                                                                                                                                                             
  CC          115   92           Reference                      35             Reference                            92             Reference                                     35             Reference                                  62    Reference                 65    Reference             
  CT          237   159          0.84(0.60,1.18)   0.314        70             0.97(0.61,1.53)       0.879          166            0.88(0.62,1.23)   0.440                       63             0.87(0.55,1.40)             0.568          110   0.86(0.59,1.26)   0.442   119   0.89(0.61,1.29)       0.536
  TT          87    55           0.79(0.51,1.23)   0.300        28             1.06(0.60,1.88)       0.851          59             0.85(0.55,1.31)   0.454                       24             0.91(0.50,1.64)             0.741          39    0.84(0.51,1.37)   0.478   44    0.89(0.55,1.44)       0.633
  CT/TT       324   214          0.83(0.60,1.14)   0.252        98             0.99(0.64,1.54)       0.954          225            0.87(0.63,1.20)   0.393                       87             0.88(0.56,1.37)             0.570          149   0.85(0.59,1.22)   0.382   163   0.89(0.62,1.27)       0.520
  rs3787016                                                                                                                                                                                                                                                                                            
  CC          149   103          Reference                      34             Reference                            101            Reference                                     36             Reference                                  70    Reference                 67    Reference             
  TC          226   145          0.95(0.69,1.32)   0.769        64             1.24(0.78,1.98)       0.371          151            1.00(0.72,1.39)   0.994                       58             1.09(0.68,1.74)             0.716          98    0.94(0.64,1.36)   0.723   111   1.11(0.77,1.61)       0.580
  TT          64    58           1.34(0.86,2.07)   0.194        35             **2.57(1.45,4.56)**   **0.001**      65             1.53(1.00,2.36)   0.053                       28             **1.92(1.07,3.46)**         **0.029**      43    1.47(0.90,2.38)   0.121   50    **1.79(1.11,2.89)**   **0.016**
  TC/TT       290   203          1.02(0.75,1.39)   0.911        99             1.48(0.96,2.29)       0.080          216            1.10(0.81,1.50)   0.549                       86             1.23(0.79,1.90)             0.361          141   1.03(0.73,1.46)   0.858   161   1.23(0.87,1.75)       0.239
  rs1456315                                                                                                                                                                                                                                                                                            
  AA          244   157          Reference                      77             Reference                            164            Reference                                     70             Reference                                  112   Reference                 122   Reference             
  GA          159   119          1.16(0.85,1.59)   0.344        46             0.90(0.59,1.37)       0.620          122            1.13(0.83,1.54)   0.451                       43             0.94(0.61,1.45)             0.794          77    1.05(0.74,1.50)   0.781   88    1.09(0.78,1.54)       0.610
  GG          36    30           1.29(0.76,2.19)   0.340        10             0.87(0.41,1.83)       0.707          31             1.28(0.76,2.16)   0.350                       9              0.86(0.39,1.88)             0.708          22    1.33(0.75,2.37)   0.335   18    1.01(0.55,1.85)       0.982
  GA/GG       195   149          1.19(0.89,1.60)   0.248        56             0.90(0.61,1.33)       0.588          153            1.16(0.86,1.55)   0.330                       52             0.93(0.62,1.40)             0.735          99    1.11(0.80,1.54)   0.552   106   1.08(0.78,1.49)       0.657
  rs7463708                                                                                                                                                                                                                                                                                            
  TT          184   139          Reference                      70             Reference                            148            Reference                                     61             Reference                                  98    Reference                 111   Reference             
  GT          211   138          0.87(0.64,1.18)   0.357        52             **0.65(0.43,0.97)**   **0.037**      138            0.81(0.59,1.09)   0.164                       52             0.75(0.49,1.14)             0.172          92    0.82(0.58,1.16)   0.261   98    0.77(0.55,1.07)       0.120
  GG          44    29           0.89(0.53,1.49)   0.653        11             0.65(0.32,1.33)       0.240          31             0.89(0.53,1.48)   0.645                       9              0.61(0.28,1.33)             0.212          21    0.90(0.51,1.60)   0.723   19    0.72(0.40,1.31)       0.282
  GT/GG       255   167          0.87(0.65,1.17)   0.344        63             **0.65(0.44,0.96)**   **0.029**      169            0.82(0.61,1.09)   0.174                       61             0.72(0.48,1.08)             0.116          113   0.83(0.60,1.16)   0.276   117   0.76(0.55,1.04)       0.090

^a^Adjusted by age and menopausal status

The bold values indicate statistically significant data

###### 

Stratified effects of SNPs in lncRNAs on breast cancer risk by the expression of ER,PR and HER-2

  Genotype    Co    ER(-)   *P* value^a^      ER(+)   *P* value^a^   PR(-)                 *P* value^a^   PR(+)   *P* value^a^      HER-2(-)   *P* value^a^   HER-2(+)              *P*value^a^                                                                  
  ----------- ----- ------- ----------------- ------- -------------- --------------------- -------------- ------- ----------------- ---------- -------------- --------------------- ------------- ---- --------------------- ----------- ----- ----------------- -------
  rs944289                                                                                                                                                                                                                                                       
  CC          115   48      Reference                 79             Reference                            63      Reference                    64             Reference                           28   Reference                         99    Reference         
  CT          237   88      0.89(0.58,1.35)   0.572   141            0.87(0.61,1.23)       0.422          100     0.77(0.52,1.13)   0.175      129            0.97(0.67,1.42)       0.890         46   0.79(0.47,1.33)       0.367       183   0.90(0.65,1.25)   0.526
  TT          87    30      0.83(0.48,1.41)   0.483   53             0.89(0.57,1.41)       0.629          42      0.87(0.54,1.41)   0.579      41             0.86(0.53,1.40)       0.544         18   0.86(0.44,1.65)       0.640       65    0.87(0.57,1.32)   0.510
  CT/TT       324   118     0.87(0.58,1.29)   0.479   194            0.88(0.62,1.23)       0.437          142     0.79(0.55,1.14)   0.208      170            0.94(0.66,1.35)       0.750         64   0.80(0.49,1.31)       0.381       248   0.89(0.65,1.22)   0.472
  rs3787016                                                                                                                                                                                                                                                      
  CC          149   49      Reference                 88             Reference                            62      Reference                    75             Reference                           31   Reference                         106   Reference         
  TC          226   85      1.19(0.79,1.80)   0.404   124            0.93(0.66,1.32)       0.695          103     1.14(0.78,1.67)   0.495      106            0.93(0.65,1.34)       0.707         35   0.72(0.42,1.22)       0.224       174   1.11(0.81,1.53)   0.524
  TT          64    32      1.53(0.90,2.63)   0.119   61             **1.69(1.08,2.64)**   **0.021**      40      1.51(0.91,2.49)   0.108      53             **1.75(1.10,2.79)**   **0.019**     26   **2.10(1.14,3.88)**   **0.017**   67    1.49(0.97,2.28)   0.069
  TC/TT       290   117     1.24(0.84,1.82)   0.287   185            1.08(0.78,1.49)       0.649          143     1.20(0.84,1.72)   0.324      159            1.09(0.77,1.52)       0.638         61   1.00(0.62,1.60)       0.986       241   1.17(0.87,1.59)   0.303
  rs1456315                                                                                                                                                                                                                                                      
  AA          244   87      Reference                 147            Reference                            108     Reference                    126            Reference                           48   Reference                         186   Reference         
  GA          159   67      1.18(0.81,1.71)   0.403   98             1.02(0.73,1.41)       0.928          83      1.16(0.82,1.65)   0.397      82             0.99(0.71,1.40)       0.974         36   1.13(0.70,1.82)       0.622       129   1.06(0.79,1.44)   0.699
  GG          36    12      0.95(0.47,1.91)   0.879   28             1.27(0.74,2.17)       0.390          14      0.89(0.46,1.72)   0.725      26             1.38(0.80,2.40)       0.247         8    1.06(0.46,2.43)       0.897       32    1.18(0.71,1.98)   0.526
  GA/GG       195   79      1.14(0.80,1.63)   0.480   126            1.06(0.78,1.44)       0.696          97      1.12(0.80,1.56)   0.513      108            1.07(0.78,1.47)       0.691         44   1.12(0.71,1.76)       0.621       161   1.09(0.82,1.44)   0.575
  rs7463708                                                                                                                                                                                                                                                      
  TT          184   80      Reference                 129            Reference                            98      Reference                    111            Reference                           44   Reference                         165   Reference         
  GT          211   74      0.81(0.56,1.17)   0.258   116            0.78(0.57,1.08)       0.130          92      0.82(0.58,1.16)   0.251      98             0.77(0.55,1.08)       0.124         40   0.79(0.49,1.27)       0.328       150   0.79(0.59,1.07)   0.127
  GG          44    12      0.64(0.32,1.27)   0.201   28             0.91(0.53,1.54)       0.711          15      0.65(0.34,1.23)   0.185      25             0.94(0.55,1.63)       0.834         8    0.71(0.31,1.63)       0.416       32    0.83(0.50,1.38)   0.479
  GT/GG       255   86      0.78(0.54,1.11)   0.170   144            0.80(0.59,1.09)       0.152          107     0.79(0.56,1.10)   0.162      123            0.80(0.58,1.10)       0.162         48   0.78(0.50,1.22)       0.278       182   0.80(0.60,1.06)   0.120

^a^Adjusted by age and menopausal status

The bold values indicate statistically significant data
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